EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cyclin‐dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration‐resistant prostate cancer

Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei iD, Yu Yin, Ju Guo, Hailiang Hu iD

Clinical and Translational Medicine · 2024

DOI: 10.1002/ctm2.1678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Haozhe Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine, Southern University of Science and Technology, Shenzhen, China. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinases, Ferroptosis, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Innovation Commission of Shenzhen Municipal Government Grants, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cyclin‐dependent kinase 12 (CDK12)‐deficient prostate cancer defines a subtype of castration‐resistant prostate cancer (CRPC) with a poor prognosis. Current therapy, including PARP inhibitors, shows minimal treatment efficacy for this subtype of CRPC, and the underlying mechanism remains elusive.

Methods

Based on bioinformatics analysis, we evaluated the relationship between CDK12 deficiency and prostate cancer patient's prognosis and treatment resistance. Furthermore, we used CRISPR‐Cas9 technology and mass spectrometry‐based metabolomic profiling to reveal the metabolic characteristics of CDK12‐deficient CRPC. To elucidate the specific mechanisms of CDK12 deficiency‐mediated CRPC metabolic reprogramming, we utilized cell RNA‐seq profiling and other molecular biology techniques, including cellular reactive oxygen species probes, mitochondrial function assays, ChIP‐qPCR and RNA stability analyses, to clarify the role of CDK12 in regulating mitochondrial function and its contribution to ferroptosis. Finally, through in vitro drug sensitivity testing and in vivo experiments in mice, we identified the therapeutic effects of the electron transport chain (ETC) inhibitor IACS‐010759 on CDK12‐deficient CRPC.

Results

CDK12‐deficient prostate cancers reprogramme cellular energy metabolism to support their aggressive progression. In particular, CDK12 deficiency enhanced the mitochondrial respiratory chain for electronic transfer and ATP synthesis to create a ferroptosis potential in CRPC cells. However, CDK12 deficiency downregulated ACSL4 expression, which counteracts the lipid oxidation stress, leading to the escape of CRPC cells from ferroptosis. Furthermore, targeting the ETC substantially inhibited the proliferation of CDK12‐deficient CRPC cells in vitro and in vivo, suggesting a potential new target for the therapy of CDK12‐deficient prostate cancer.

Conclusions

Our findings show that energy and lipid metabolism in CDK12‐deficient CRPC work together to drive CRPC progression and provide a metabolic insight into the worse prognosis of CDK12‐deficient prostate cancer patients. Key points CDK12 deficiency promotes castration‐resistant prostate cancer (CRPC) progression by reprogramming cellular metabolism. CDK12 deficiency in CRPC leads to a more active mitochondrial electron transport chain (ETC), ensuring efficient cell energy supply. CDK12 phosphorylates RNA Pol II to ensure the transcription of ACSL4 to regulate ferroptosis. Mitochondrial ETC inhibitors exhibit better selectivity for CDK12‐deficient CRPC cells, offering a promising new therapeutic approach for this subtype of CRPC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent KinasesFerroptosisProstatic Neoplasms, Castration-ResistantAnimalsHumansMaleMiceCell Line, TumorDisease ProgressionOxadiazolesPiperidines

Stichwörter der Autor:innen

CDK12CRPCferroptosismetabolism

Substanzen

CDK12 protein, humanCyclin-Dependent KinasesIACS-010759OxadiazolesPiperidinesCDK12 protein, mouse

Autor:innen und Institutionen

  • Department of Biochemistry, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Key University Laboratory of Metabolism and Health of Guangdong, Southern University of Science and Technology, Shenzhen, China.

ORCID-Profile: Qiang Wei, Hailiang Hu

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Innovation Commission of Shenzhen Municipal Government Grants
  • Natural Science Foundation of Guangdong Province
  • Key Natural Science Research Project of Anhui Universities

Zitieren

APA

Zhang, H., Zhou, Y., Feng, Y., Hou, W., Chen, Y., Xing, Z., Zhang, Y., Wei, Q., Yin, Y., Guo, J., & Hu, H. (2024). Cyclin‐dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration‐resistant prostate cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1678

Vancouver

Zhang H, Zhou Y, Feng Y, Hou W, Chen Y, Xing Z, et al. Cyclin‐dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration‐resistant prostate cancer. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.1678

BibTeX
@article{Zhang2024,
  author = {Zhang, Haozhe and Zhou, Yi and Feng, Yating and Hou, Wenli and Chen, Yafei and Xing, Zengzhen and Zhang, Yifan and Wei, Qiang and Yin, Yu and Guo, Ju and Hu, Hailiang},
  title = {Cyclin‐dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration‐resistant prostate cancer},
  journal = {Clinical and Translational Medicine},
  year = {2024},
  doi = {10.1002/ctm2.1678}
}
Kostenlos starten →